日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2-Positive Solid Tumors.

针对 Claudin 18.2 阳性实体瘤表达 T 细胞抗原偶联物的 T 细胞的临床前开发

Xu Stacey X, Wang Ling, Ip Philbert, Randhawa Ritu R, Benatar Tania, Prosser Suzanna L, Lal Prabha, Khan Alima Naim, Nitya-Nootan Thanyashanthi, Thakor Gargi, MacGregor Heather, Hayes Danielle L, Vucicevic Andrea, Mathew Princy, Sengupta Sadhak, Helsen Christopher W, Bader Andreas G

IMMU-01. TEMOZOLOMIDE-RESISTANT CAR-T ENHANCES GLIOBLASTOMA CLEARANCE BY CONCURRENT CHEMOTHERAPY AND IMMUNOTHERAPY

IMMU-01. 替莫唑胺耐药CAR-T细胞通过同步化疗和免疫疗法增强胶质母细胞瘤的清除

Zhang, Zhuo; Fu, Datian; Cao, Yingdong; Sampath, Prakash; Sengupta, Sadhak; Sengupta, Sudarshana; Junghans, Richard

Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy

白细胞介素-13受体α2靶向胶质母细胞瘤免疫疗法

Sengupta, Sadhak; Thaci, Bart; Crawford, Andrew C; Sampath, Prakash

The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma

IL-17A 和 T 辅助细胞 17 在实验性小鼠脑肿瘤和人类胶质瘤中的存在

Wainwright, Derek A; Sengupta, Sadhak; Han, Yu; Ulasov, Ilya V; Lesniak, Maciej S

Challenges in clinical design of immunotherapy trials for malignant glioma

恶性胶质瘤免疫疗法试验临床设计面临的挑战

Rolle, Cleo E; Sengupta, Sadhak; Lesniak, Maciej S